Efficacy and safety of calcium antagonists intreatment of hypertension in the alderly: focuson amlodipine

Study objective. To investigate efficacy and safety of amlodipine (Cardilopine) in the elderly hypertensive patients.
Patients and methods. 34 pateints on 65-79 years old with uncomplicated stage 1-3 hypertension were studied. Systolodiastoloc hypertension (SDH) was in 61,76% of cases, isilated systolic hypertension (ISH) in 38,24%. Hypertension duration was 11,18±1,26 yrs. Crdilopine EGIS) was administrated once daily in dose 5 mg. After one month of treatment the dose was increased or hydrochlorothiazide added. 24 blood pressure monitoring was performed at baseline and after 3 and 12 months of treatment. Treatment efficacy was evaluated according to criteria of Kobalava G (2002). Drug safety was analyzed according to side effects registration.
Results. The blood pressure was reduced by 39,07/16,27 mm Hg and 21,69/3,60 mm Gh respectively (p<0,001), pulse pressure was also reduced. Blood pressure variability was normalized during 24-hors and mean daytime. The morning surge of blood pressure also decreased. The was a tendency for normalization of diurnal pressure rhythm - the number of "night-peakers" reduced and proportion of "dippers" increased. Effect of therapy was observed in 93,33% of patients.
Conclusions. Cardilopin is effective and well-tolerated in elderly hypertensive patients.

Hypertension , elderly , ambulatory blood pressure monitoring , amlodipine

1. Арабидзе Г.Г., Белоусов Ю.Б., Карпов Ю.А. Артериальная гипертония. Москва, Наука 1999; 139.

2.

3. Арутюнов Г.П. Проблемные вопросы артериальной гипертонии. Consilium medicum 2001; Экстра-выпуск: 5-7.

4.

5. Барсуков А.В., Горячева А.А. Клинико-патогенетические аспекты вариабельности артериального давления при артериальной гипертензии. Кардиология 2003; 43 (2): 82-86.

6.

7. Горбунов В.М. Значение 24-часового мониторирования в выявлении и лечении артериальной гипертензии. Кардиология 1995; 35 (6): 64-70.

8.

9. Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериального давления: методические аспекты и клиническое значение. Москва 1999; 234.

10.

11. Кобалава Ж.Д., Котовская Ю.В., Асеева О.А. и др. Клинико-демографические характеристики различных вариантов артериальной гипертонии у пожилых (по результатам Российской научно-практической программы АРГУС). Тер. архив 2002; 2: 47-51.

12.

13. Лазебник Л.Б., Комиссаренко И.А., Милюкова О.М. и др. Артериальная гипертония у пожилых. Врач 2000; 7: 25-27.

14.

15. Лизогуб И.В., Купчинская Е.Г., Лизогуб Г.В. Длительное применение амлодипина в лечении пациентов с гипертонической болезнью. Укр. кардioл. журн. 2002; 5: 45-50.

16.

17. Моисеев B.C., Кобалава Ж.Д. АРГУС. Артериальнаягипертония у лиц старших возрастных групп. Монография.Москва, ООО «Медицинское информационное агентство»2002; 448.

18.

19. Преображенский Д.В., Сидоренко Б.А., Шабаева Е.Н. Амлодипин - антагонист кальция третьего поколения. Кардиология 1998; 2: 66-72.

20.

21. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов Всероссийского научного общества кардиологов, секция артериальной гипертонии ВНОК. Кардиоваскулярная терапия и профилактика 2004; Приложение: С.20.

22.

23. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. и др. Суточное мониторирование артериального давления при гипертонии. Метод. вопросы. Москва 1999; 52 с.

24.

25. Свищенко Е.П., Ярынкина Е.А., Мхитарян Л.С. и др. Влияние амлодипина на суточные колебания артериального давления и гуморальный профиль артериальной гипертензии. Укр. кардioл. журн. 1998; 5: 34-38.

26.

27. Свищенко Е.П., Коваленко В.Н. Артериальная гипертензия, Киев, Морион 2001; 527 с.

28.

29. Токарь А.В., Ена Л.М. Артериальная гипертензия в пожилом возрасте. Киев, Здоров'я 2000; 220.

30.

31. Шальнова С.А. Факторы риска сердечно-сосудистых заболеваний и показатели ожидаемой продолжительности жизни населения России (по результатам обследования национальной представительной выборки): [Автореф. дис. ... д-ра мед. наук]. Москва 1999; 46.

32.

33. Шевченко О.П., Яхно Н.Н., Праскурничий Е.А., Парфенов В. А. Артериальная гипертония и церебральный инсульт. Москва, Реаформ 2001; 191.

34.

35. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-2997.

36.

37. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.

38.

39. Gong L., Zhang W., Zhu Y., Zhu J., 11 collaborative centres in the Shanghai area, Kong D, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237-1245.

40.

41. Guidelines Committee - 2003. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053.

42.

43. Hamet P., Gong L. Antihypertensive therapy debate: contribution from the Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertension 1996; 14 (Suppl. 4): S9-S14.

44.

45. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patents with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998: 351: 175517-62.

46.

47. Hansson L., Lindholm L.H., Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.

48.

49. Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and P-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.

50.

51. Ichihara A., Nayashi M., Koura Y. et al. Long-term effects of intensive blood-pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens 2003; 16 (11 Pt 1): 959-965.

52.

53. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.

54.

55. Kario K., Matsuo T., Kobayashy H. et al. Noctural fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 24: 793-801.

56.

57. Kikuya M., Hozawa A., Ohokubo T. et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama Study. Hypertension 2000; 36: 901-906.

58.

59. Kloner R.A., Sowers J.R., DiBona G.F. et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713-722.

60.

61. Liu L., Wang J.G., Gong L. et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hum Hypertens 1998; 16: 1823-1829.

62.

63. Malacca E., Gnemmi A.E., Romagnoli A. et al. on behalf of the SHELL study group. Systolic Hypertension in the Elderly: Long-term Lacidipine treatment. Objective, protocol, and organization. J Cardiovasc Pharmacol 1994; 23 (Suppl 5): S62-S66.

64.

65. National Intervention Cooperative Study in Elderly Hypertensives (NICS-EH) Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34:1129-33.

66.

67. Opie L.H., Shall R. Evidence-based evaluation of calcium channel blockers for hypertension. Equality of mortality and cardiovascular risk relative to conventional therapy J Am Coll Cardiol 2002; 39: 315-22.

68.

69. Sander D., Klingelhier J. Diurnal systolic blood pressure variability is the strongest predictor of early carotid atherosclerosis. Neurology 1996; 7: 500-507.

70.

71. Staessen J., Fagard R., Thijs L. et al. Randomized double-blind comparison of placebo and active treatment for olderpatients with isolated systolic hypertension. The SystolicHypertension in Europe (Syst-Eur) Trials Investigators. Lancet1997; 350: 757-764.

72.

73. Wang J.G., Liu G., Wang X. et al. Long-term bloodpressure control in older Chinese patients with isolated systolichypertension: a progress report on the Syst-China trial. J HumHypertens 1996; 10: 735-742.

74.

75. Webster J., Fowler G., Jeffers Т.А. et al. A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension. Brit J Clin Pharm 1993; 35 (5): 499-505.

76.

77. Zanchetti A. Evaluating the benefits of an antihypertensive agent using trial based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 1995; 13 (Suppl 4): S35-39.

78.